icone plus
Contact
Abonnez-vous aux actualités
Autorisation d’accès précoce refusée à la spécialité DUPIXENT (dupilumab).
Voir aussi
Décision d'accès précoce
14/11/2024
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
adxFL3mYJxPzxdVS